The CCR7 expression is consistently observed in both resting and proliferative compartments; in different groups of CLL patients regardless of the stage at diagnosis; unfavorable flow cytometry (CD38, ZAP-70, VLA-4) or genetic (IGHV mutated/un-mutated status, p53 mutated/deleted, ATM mutated/deleted, trisomy 12, NOTCH1 mutations) prognostic markers; previous treatments or the presence of relapsed or refractory (r/r) disease to different standard-of-care (SOC) therapies (Table 1). The gene discussed is CCR7; the disease is B-cell chronic lymphocytic leukemia.